Canaccord Genuity lowered shares of Concordia Healthcare Corp. (NASDAQ:CXRX) to a buy rating in a research report sent to investors on Friday. They currently have $10.00 target price on the stock.

Analyst Recommendations for Concordia Healthcare Corp. (NASDAQ:CXRX)

A number of other research firms have also issued reports on CXRX. RBC Capital Markets reaffirmed an outperform rating and issued a $35.00 target price on shares of Concordia Healthcare Corp. in a research note on Tuesday, August 23rd. Zacks Investment Research raised Concordia Healthcare Corp. from a hold rating to a buy rating and set a $23.00 target price on the stock in a research note on Wednesday, July 13th. CIBC lowered Concordia Healthcare Corp. from a sector perform rating to an underperform rating and set a $7.80 target price on the stock. in a research note on Monday, August 15th. TD Securities reaffirmed a buy rating and issued a $37.00 target price (down previously from $45.00) on shares of Concordia Healthcare Corp. in a research note on Wednesday, June 29th. Finally, Royal Bank Of Canada reaffirmed an outperform rating and issued a $73.00 target price on shares of Concordia Healthcare Corp. in a research note on Thursday, May 26th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $37.79.

Concordia Healthcare Corp. (NASDAQ:CXRX) opened at 5.12 on Friday. The firm’s market capitalization is $261.21 million. Concordia Healthcare Corp. has a 1-year low of $4.80 and a 1-year high of $69.60. The company’s 50-day moving average price is $9.89 and its 200 day moving average price is $21.62.

Concordia Healthcare Corp. (NASDAQ:CXRX) last posted its earnings results on Friday, August 12th. The company reported $1.38 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.38. Concordia Healthcare Corp. had a positive return on equity of 25.18% and a negative net margin of 81.80%. The firm had revenue of $231.70 million for the quarter, compared to analyst estimates of $229.76 million. The business’s revenue was up 208.1% on a year-over-year basis. On average, equities analysts anticipate that Concordia Healthcare Corp. will post $5.21 EPS for the current year.

A number of institutional investors have recently bought and sold shares of CXRX. Norges Bank purchased a new position in Concordia Healthcare Corp. during the fourth quarter worth approximately $15,141,000. CIBC World Markets Inc. increased its position in Concordia Healthcare Corp. by 22.3% in the first quarter. CIBC World Markets Inc. now owns 172,634 shares of the company’s stock worth $4,419,000 after buying an additional 31,517 shares during the period. PCJ Investment Counsel Ltd. increased its position in Concordia Healthcare Corp. by 14.0% in the first quarter. PCJ Investment Counsel Ltd. now owns 676,390 shares of the company’s stock worth $17,382,000 after buying an additional 83,000 shares during the period. Goldman Sachs Group Inc. increased its position in Concordia Healthcare Corp. by 15.5% in the first quarter. Goldman Sachs Group Inc. now owns 79,981 shares of the company’s stock worth $2,047,000 after buying an additional 10,734 shares during the period. Finally, Geode Capital Management LLC increased its position in Concordia Healthcare Corp. by 12.4% in the first quarter. Geode Capital Management LLC now owns 20,553 shares of the company’s stock worth $526,000 after buying an additional 2,270 shares during the period. Institutional investors and hedge funds own 33.93% of the company’s stock.

About Concordia Healthcare Corp.

5 Day Chart for NASDAQ:CXRX

Receive News & Ratings for Concordia Healthcare Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concordia Healthcare Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.